Srdan Verstovsek, MD, PhD, discusses the impacts of an analysis demonstrating longer survival in patients with myelofibrosis who received ruxolitinib versus those who didn’t.
Srdan Verstovsek, MD, PhD
Articles by Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, discusses how research and future clinical trials can better determine the benefit of ruxolitinib as treatment of patients with myelofibrosis, which is often measured in improvements in the quality of life and spleen reductions.
Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.
Srdan Verstovsek, MD, PhD, discusses the data seen in the phase 2 trial of CPI-0610 with or without ruxolitinib in patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, discusses the potential role of CPI-0610 as treatment of patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the importance of intervention in chronic phase myelofibrosis.<br />
Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, discusses the most recent developments in diagnosing polycythemia vera.
Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, Department of Leukemia, discusses identifying and treating different myeloproliferative neoplasms (MPNs).
Srdan Verstovsek, MD, PhD, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.